Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 24Breast Neoplasms 13Uterine Cervical Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Colorectal Neoplasms 9Melanoma 8Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 6Lung Neoplasms 5Fallopian Tube Neoplasms 5Vaginal Neoplasms 4Urogenital Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Penile Neoplasms 4Oropharyngeal Neoplasms 4Anus Neoplasms 4Vulvar Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Kidney Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Thyroid Carcinoma, Anaplastic 2Testicular Neoplasms 2Testicular Germ Cell Tumor 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2

Interventions

pembrolizumab 4atezolizumab 2Nivolumab 2fludarabine 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1Carboxylesterase 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × aldesleukin × Gynecologic × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡